Abbvie Inc. vs Biogen Inc.
ABBV vs BIIB — side-by-side comparison from reported financials. ABBV leads 7, BIIB leads 3 of 10 comparable metrics.
Abbvie Inc.
ABBV · Healthcare
$276.43+1.47%Mixed
Biogen Inc.
BIIB · Healthcare
$225.71+3.33%Strained
| Metric | ABBV | BIIB |
|---|---|---|
| Price | $276.43 | $225.71 |
| Market cap | $488B | $33.4B |
| Revenue (TTM) | $64.4B | $10.0B |
| Revenue growth | +1.8% | -0.9% |
| Net margin | 9.8% | 8.3% |
| Free cash flow | $18.2B | $2.70B |
| Net cash (debt) | ($56.2B) | $807M |
| 1-year price return | +19.8% | +50.9% |
| P/E | 77.4 | 40.0 |
| P/E vs own history (cheap-side %) | 23% | 1% |
| Dividend yield | 2.45% | — |
| Return on equity | 96% | 5% |
| Altman Z-score | 2.33 | — |
| CV checks passed | 9 of 11 | 8 of 11 |
| Employees | 57,000 | 7,500 |
Full résumé-style profiles: ABBV CV · BIIB CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.